Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y)

Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y)

BackgroundLAIs with longer dosing intervals appear to be associated with improved clinical outcomes and added real-world benefits in the management of schizophrenia. Paliperidone palmitate six-monthly (PP6M) LAI provides the longest dosing interval, twice-yearly dosing, among all currently available...

Full description

Saved in:
Bibliographic Details
Main Authors: Sofía Manchado Perero, Ana Rodríguez Lorente, Alba García-Pérez, Guillermo Isidro García, Luis Alberto Forcen-Muñoz, Santiago Ovejero García, Rocío Sáez Povedano, Ana Luisa González-Galdámez, Laura Mata Iturralde, Mariluz Ramirez Bonilla, Paloma Fuentes-Pérez, Claudia Ovejas-Catalán, Paula Suárez-Pinilla, Blanca Fernández Abascal, Miguel Omaña Colmenares, María Pilar Campos-Navarro, Enrique Baca-García, Ana Lara Fernández, Sergio Benavente-López, Alberto Raya Platero, Miguel Barberán Navalón, Sergio Sánchez-Alonso, Javier Vázquez-Bourgon, Sofia Pappa, Juan Antonio García-Carmona
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Psychiatry
Subjects:
paliperidone-palmitate 6-monthly
schizophrenia
long-acting injectable antipsychotics
mirror-image study
hospital admission
CGI (Clinical Global Impressions)
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1540213/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1540213/full

Similar Items